Feature | September 25, 2012

Physicians are seeing more patients and performing fewer studies on those patients, report notes

MedAxiom ASNC Nuclear Imaging

September 25, 2012 — A new survey reveals that cardiologists around the United States are seeing more patients than ever before, yet performing fewer advanced nuclear tests on those patients on average. The survey cites a change in the approach to the delivery of cardiovascular care, as well as continued concerns about economic conditions, as reasons for the decline.

Despite the decline, the findings confirm cardiologists are providing Americans with technology-based healthcare that is capable of delivering better diagnostic capabilities — an issue of increasing importance given the increasing number of older citizens requiring cardiac care.

MedAxiom, a national source of quantifiable information about the state of cardiology practices, jointly conducted the survey with the American Society of Nuclear Cardiology (ASNC). More than 110 practices, representing more than 2,000 cardiologists, took part in the survey, which was released at ASNC's annual conference in early September.

The survey reveals that in 2011, on average, cardiologists recorded more than 2,100 patient visits, up more than 29 percent since 2004. At the same time, however, they performed an average of 356 imaged stress studies last year, such as stress echo tests, single-photon emission computerized tomography (SPECT) tests or positron emission tomography (PET) tests to detect potential coronary problems such as blocked arteries or reduced pumping efficiency. That number remained, on average, largely flat over the same eight-year period, up only 2 percent.

Expressed as a ratio, however, the survey revealed that these tests were performed on one of every eleven cardiology patients last year, as opposed to one of every seven in 2008. "Put simply," the survey authors note, "physicians are seeing more patients and performing fewer studies on those patients." The study cited several reasons, such as:

  • Increasing adoption of appropriate use criteria;
  • Higher deductibles and co-pays for those with insurance;
  • Increased awareness of radiation optimization;
  • The use of provider-based billing by integrated cardiology practices; and
  • An intermittent shortage of molybdenum-99, a key radioactive isotope in conducting the tests.


"In the face of increasing challenges, America's cardiologists have made a commitment of continuing to provide superior healthcare," said Jennifer Linville, CEO of MedAxiom. "At the same time, many recognize the advantages of nuclear cardiac imaging tests as an important tool to identify potential coronary disease among their patients. Balancing the two, cardiologists have committed to the selective and responsible administration of these tests in a way that contributes to the continued health of the people who depend on them."

"Nuclear cardiology imaging plays, and will continue to play, an important role diagnosing and treating heart disease." said John Mahmarian, M.D., president of ASNC. "Our doctors have been vigilant in prescribing the appropriate use of these tests as defined by our participation in the Choosing Wisely initiative. As healthcare evolves in the United States, we intend to continue clearly defining the patient-centered approach to cardiovascular imaging and optimizing the value received from it. Our goal is to continue to provide both quality and value to our patients."

For more information: www.medaxiom.com, www.asnc.org


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Subscribe Now